期刊文献+

BRAF V600E突变与经典型甲状腺乳头状癌患者临床病理特征的相关性 被引量:5

Relationship between BRAF V600E mutation and the clinicopathological features of patients with classical papillary thyroid carcinoma
原文传递
导出
摘要 目的 探讨BRAF V600E突变与经典型甲状腺乳头状癌(PTC)患者临床病理特征的相关性.方法 回顾性分析226例确诊为经典型PTC患者的临床病理资料,用实时荧光定量聚合酶链反应检测BRAF V600E突变,分析BRAF V600E突变与患者临床病理特征的相关性.结果 226例经典型PTC患者的BRAF V600E突变率为76.5%(173/226).不同性别、年龄、肿瘤个数、肿瘤侧别以及淋巴结转移情况患者的BRAF V600E突变率差异均无统计学意义(均P> 0.05),而肿瘤直径>1.0cm者的BRAF V600E突变率为81.8%(135/165),高于≤1.0cm者的62.3%(38/61),两者差异有统计学意义(x2=9.456,P=0.002).结论 BRAF V600E突变可作为预测经典型PTC预后的一个重要指标.
出处 《肿瘤研究与临床》 CAS 2016年第5期338-340,共3页 Cancer Research and Clinic
  • 相关文献

参考文献10

  • 1Moon HJ, Kim EK, Chung WY, et al. BRAF mutation in fine-needle aspiration specimens as a potential predictor for persistence/recurrence in patients with classical papillary thyroid carcinoma larger than 10 mm at a BRAF mutation prevalent area [ J ]. Head Neck, 2015, 37 ( 10 ) : 1432-1438.
  • 2Niederer-Wtist SM, Jochum W, Ftirbs D, et al. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer [J]. Surgery, 2015, 157 ( 1 ) : 119-125.
  • 3Capelli L, Marfisi C, Puccetti M, et al. Role of BRAF molecular analysis in the management of papillary thyroid carcinoma: analysis of cytological and histological samples [ J ]. Cytopathology, 2015, 26 ( 5 ) : 297-302.
  • 4Kim MH, Bae JS, Lira DJ, et al. Quantification of BRAFV6OOE alleles predicts papillary thyroid cancer progression [ J ]. Endocr Relat Cancer, 2014, 21 (6) : 891-902.
  • 5Suh Y J, Kwon H, Kim S J, et al. Factors affecting the locoregional recurrence of conventional papillary thyroid carcinoma after surgery:a retrospective analysis of 3 381 patients [ J ]. Ann Surg Oncol, 2015, 22 ( 11 ) : 3543-3549.
  • 6Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer[J]. Mol Cell Endocrinol, 2010, 321 ( 1 ) : 86-93.
  • 7Li WF, Wang G, Zhao ZB, et al. High expression of metadherin correlates with malignant pathological features and poor prognostic significance in papillary thyroid carcinoma [ J ]. Clin Endocrinol ( Oxf ), 2015, 83 ( 4 ) : 572-580.
  • 8Melo M, da Rocha AG, Vinagre J, et al. Coexistence of TERT promoter and BRAF mutations in papillary thyroid carcinoma:added value in patient prognosis? [ J ]. J Clin Oncol, 2015, 33 ( 6 ) : 667- 668.
  • 9Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence [ J ]. J Clin Oncol, 2014, 32 ( 25 ) : 2718-2726.
  • 10Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer [J]. JAMA, 2013, 309 (14): 1493-1501.

同被引文献28

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部